DexCom Inc (DXCM) company profile
Close on Nov 17, 2026Market cap $30.60BP/E 32.3Yield –
About DexCom
Surgical & Medical Instruments & Apparatus, SIC 3841
DexCom, Inc. is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes management and metabolic health. Its core product lineup features wearable sensor systems, including the Dexcom G7, G7 15 Day, and Dexcom ONE+, which continuously track glucose levels and wirelessly transmit readings and alerts to compatible receivers, mobile applications, and connected insulin delivery devices. The company also offers Stelo, an over-the-counter glucose biosensor designed for adults with prediabetes or non-insulin-treated Type 2 diabetes. Its customer base primarily comprises individuals with Type 1 and Type 2 diabetes, their caregivers, healthcare professionals, and health-conscious adults seeking to track glucose trends.
The company operates globally, serving markets across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa through direct sales organizations, distribution partnerships, and e-commerce platforms. DexCom primarily manufactures its devices at facilities located in Mesa, Arizona, and Penang, Malaysia, with an additional manufacturing facility under construction in Athenry, Ireland, and facilities in San Diego, California. The company is based in the United States.
Summary of the business section of DexCom's latest annual report, written by StockData.
Company profile
Company
- Legal name
- DexCom Inc
- Founded
- 2006
- Headquarters
- San Diego, CA
- Address
- 6340 Sequence Drive 92121
- Phone
- (858) 200-0200
- Website
- dexcom.com
- Employees
- 11,100, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- DXCM
- Exchange
- Nasdaq
- IPO date
- Apr 14, 2005
- Shares outstanding
- 373M, Oct 22, 2026
- Public float
- $34.20B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 4-for-1, Jun 13, 2022
- SEC CIK
- 1093557
- CUSIP
- 252131107
- ISIN
- US2521311074
- FIGI
- BBG000QTF8K1
- Share class FIGI
- BBG001SKZG99
- LEI
- 549300YSK3QDSFR5EU59
- EIN
- 33-0857544
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jacob Steven Leach | President, CEO, and Director | 464,753 |
| Kevin R. Sayer | Executive Chair, Director | 302,214 |
| Sadie Stern | EVP Chief People & Culture Off | 119,462 |
| Michael Jon Brown | EVP Chief Legal Compliance Off | 96,734 |
| Jereme M. Sylvain | EVP, COO & CFO | 145,377 |
| Jon Coleman | EVP, Chief Commercial Officer | 95,450 |
| Matthew Vincent Dolan | EVP, Strategy & Corporate Dev | 42,044 |
| Euan A. Ashley | Director | 12,731 |
| Nicholas Augustinos | Director | 34,868 |
| Glenn S. Boehnlein | Director | 5,883 |
| Bridgette P. Heller | Director | 29,570 |
| Mark G. Foletta | Director | 55,183 |
| Albert Frederick Osterloh IV | Director | 8,691 |
| Rimma Driscoll | Director | 17,319 |
| Renee D. Gala | Director | 12,486 |
| Steven R. Altman | Director | 69,232 |
| Richard Alexander Collins | Director | 45,767 |
| Kyle Malady | Director | 28,242 |
| Eric Topol | Director | 380,545 |
| Karen M. Dahut | Director | 17,779 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Jacob Leach | $7.99M | $6.68M | $6.61M | $72 | $79 |
| FY2025 Kevin Sayer | $16.28M | $12.99M | $6.61M | $72 | $79 |
| FY2024 | $15.83M | -$8.69M | $5.62M | $84 | $79 |
| FY2023 | $15.71M | $23.00M | $5.02M | $134 | $75 |
| FY2022 | $15.44M | $5.74M | $4.44M | $123 | $79 |
| FY2021 | $11.99M | $36.05M | $4.96M | $145 | $104 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Jacob Leach President & Chief Executive Officer | $768.96K | $5.94M | $1.16M | $116.16K | $7.99M | +35% |
| Kevin Sayer Executive Chairman | $1.21M | $13.85M | $1.14M | $70.85K | $16.28M | +3% |
| Jereme Sylvain EVP, Chief Financial Officer | $646.62K | $5.94M | $465.57K | $29.65K | $7.08M | +21% |
| Michael Brown EVP, Chief Legal Officer | $631.63K | $5.24M | $454.77K | $14.96K | $6.34M | +28% |
| Jon Coleman EVP, Chief Commercial Officer | $491.51K | $5.83M | $353.89K | $68.86K | $6.75M | – |
| Sadie Stern EVP, Chief Human Resources Officer | $571.21K | $5.24M | $411.27K | $28.16K | $6.25M | +27% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 14, 2005
- Offer price
- $12.00
- Securities offered
- 4,700,000
- Gross proceeds
- $56.40M
- Exchange
- Nasdaq
- First trading day
- Apr 14, 2005
- First-day close
- $11.74-2.2%
- Lock-up ends (est.)
- Oct 11, 2005
“Per Share Total Initial public offering price $ 12.00 $ 56,400,000 Underwriting discount $ 0.84 $ 3,948,000 Proceeds, before expenses, to DexCom, Inc.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we have approximately 11,100 employees around the globe, including 11,000 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 25, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Apr 14, 2005 | IPO | Initial public offering priced (424B4 prospectus) |
See a number that looks wrong?